{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:23:42Z","timestamp":1757615022556,"version":"3.44.0"},"reference-count":34,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"6","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Background: This study aimed to analyze the expressions of CD184 and CD269 in patients with newly diagnosed multiple myeloma (MM) in China and explored their potential association with prognosis. Methods: This retrospective study recruited 100 patients with MM and 113 healthy controls who attended Beijing Chaoyang Hospital Shijingshan District between June 2020 and December 2023. The association between CD184 and CD269 expression and patient survival outcomes was assessed using univariable and multivariable Cox proportional hazards regression analyses, alongside Kaplan-Meier survival curves. Results: Both CD184 and CD269 mRNA were elevated in MM patients compared to controls (P&lt;0.05). By qualitative analysis, it was seen that both CD184+ and CD269 patients had a reduced prognostic overall survival (OS) (P&lt;0.05). Similarly, detection of CD184 and CD269 expression was effective in predicting prognostic mortality in patients. Conclusions: CD184 and CD269 may serve as valuable prognostic markers in MM patients.<\/jats:p>","DOI":"10.5937\/jomb0-56987","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T03:22:41Z","timestamp":1744600961000},"page":"1210-1218","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of prognostic risk of death in patients with multiple myeloma based on CD184 and CD269: A retrospective analysis"],"prefix":"10.5937","volume":"44","author":[{"given":"Hong","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mulan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3964","reference":[{"doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 2024; 99(9): 1802-24.;","key":"ref1","DOI":"10.1002\/ajh.27422"},{"doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger). Ann Oncol 2021; 32(3): 309-22.;","key":"ref2","DOI":"10.1016\/j.annonc.2020.11.014"},{"unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Multiple Myeloma. Version 1.2025. Fort Washington: National Comprehensive Cancer Network; 2024.;","key":"ref3"},{"doi-asserted-by":"crossref","unstructured":"Yen JH, Chang CC, Hsu HJ, Yang CH, Mani H, Liou JW. C-X-C motif chemokine ligand 12-C-X-C chemokine receptor type 4 signaling axis in cancer and the development of chemotherapeutic molecules. Tzu Chi Med J 2024; 36(3): 231-9.;","key":"ref4","DOI":"10.4103\/tcmj.tcmj_52_24"},{"doi-asserted-by":"crossref","unstructured":"Yu J, Zhou X, Shen L. CXCR4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors. Molecules 2023; 28(12).;","key":"ref5","DOI":"10.3390\/molecules28124707"},{"doi-asserted-by":"crossref","unstructured":"Kopinska A, Krawczyk-Kulis M, Wieczorkiewicz-Kabut A, Koclega A, Jagoda K, Dziaczkowska-Suszek J, et al. Effect of transplanted cells with CD184 and CD26 expressions and reconstitution of CD3+ lymphocyte population on long-term survival after autologous hematopoietic stem cell transplantation for multiple myeloma. Exp Hematol 2023; 127: 52-8 e1.;","key":"ref6","DOI":"10.1016\/j.exphem.2023.08.007"},{"doi-asserted-by":"crossref","unstructured":"Cornelis R, Chang HD, Radbruch A. Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells. Curr Opin Immunol 2021; 71: 97-102.;","key":"ref7","DOI":"10.1016\/j.coi.2021.06.012"},{"doi-asserted-by":"crossref","unstructured":"Slamanig SA, Nolte MA. The Bone Marrow as Sanctuary for Plasma Cells and Memory T-Cells: Implications for Adaptive Immunity and Vaccinology. Cells 2021; 10(6).;","key":"ref8","DOI":"10.3390\/cells10061508"},{"doi-asserted-by":"crossref","unstructured":"Cattaneo I, Valgardsdottir R, Cavagna R, Spinelli O, Bartoletti-Stella A, Capellari S, et al. Genetic defects of gamma-secretase genes in a multiple myeloma patient with high and dysregulated BCMA surface density: A case report. Br J Haematol 2024; 204(2): 571-5.;","key":"ref9","DOI":"10.1111\/bjh.19168"},{"doi-asserted-by":"crossref","unstructured":"Jakubikova J, Cholujova D, Beke G, Hideshima T, Klucar L, Leiba M, et al. Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma. JCI Insight 2023; 8(3).;","key":"ref10","DOI":"10.1172\/jci.insight.159924"},{"unstructured":"Chinese Hematology A, Chinese Society of H. Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision). Zhonghua Nei Ke Za Zhi 2022; 61(5): 480-7.;","key":"ref11"},{"doi-asserted-by":"crossref","unstructured":"Li L, Li X, Shang A, Zhao Y, Jin L, Zhao M, et al. Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma: A real-world retrospective study. Medicine (Baltimore) 2022; 101(40): e30988.;","key":"ref12","DOI":"10.1097\/MD.0000000000030988"},{"doi-asserted-by":"crossref","unstructured":"Hanamura I. Gain\/Amplification of Chromosome Arm 1q21 in Multiple Myeloma. Cancers (Basel) 2021; 13(2).;","key":"ref13","DOI":"10.3390\/cancers13020256"},{"doi-asserted-by":"crossref","unstructured":"Wang T, Peng X, Qiao W, Xing Y, Yang J, Zhao J. The role of CT in PET\/CT for assessing diffuse infiltration of bone marrow in multiple myeloma using the Durie-Salmon PLUS staging system. Mol Clin Oncol 2020; 13(1): 13-8.;","key":"ref14","DOI":"10.3892\/mco.2020.2039"},{"doi-asserted-by":"crossref","unstructured":"D'Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol 2022; 40(29): 3406-18.;","key":"ref15","DOI":"10.1200\/JCO.22.02228"},{"doi-asserted-by":"crossref","unstructured":"Ullah TR. The role of CXCR4 in multiple myeloma: Cells' journey from bone marrow to beyond. J Bone Oncol 2019; 17: 100253.;","key":"ref16","DOI":"10.1016\/j.jbo.2019.100253"},{"doi-asserted-by":"crossref","unstructured":"Giallongo C, Dulcamare I, Tibullo D, Del Fabro V, Vicario N, Parrinello N, et al. CXCL12\/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment. Oncogenesis 2022; 11(1):6.;","key":"ref17","DOI":"10.1038\/s41389-022-00380-z"},{"doi-asserted-by":"crossref","unstructured":"Khare T, Bissonnette M, Khare S. CXCL12-CXCR4\/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies. Int J Mol Sci 2021; 22(14).;","key":"ref18","DOI":"10.3390\/ijms22147371"},{"doi-asserted-by":"crossref","unstructured":"Floranovic MP, Velickovic LJ. Effect of CXCL12 and Its Receptors on Unpredictable Renal Cell Carcinoma. Clin Genitourin Cancer 2020; 18(4): e337-e42.;","key":"ref19","DOI":"10.1016\/j.clgc.2019.11.004"},{"doi-asserted-by":"crossref","unstructured":"Kogue Y, Kobayashi H, Nakamura Y, Takano T, Furuta C, Kawano O, et al. Prognostic Value of CXCL12 in Non-Small Cell Lung Cancer Patients Undergoing Tumor Resection. Pharmaceuticals (Basel) 2023; 16(2).;","key":"ref20","DOI":"10.3390\/ph16020255"},{"doi-asserted-by":"crossref","unstructured":"Li X, Bao Y, Li Z, Teng P, Ma L, Zhang H, et al. Employing antagonistic C-X-C motif chemokine receptor 4 antagonistic peptide functionalized NaGdF(4) nanodots for magnetic resonance imaging-guided biotherapy of breast cancer. Sci Rep 2024; 14(1): 15764.;","key":"ref21","DOI":"10.1038\/s41598-024-66645-2"},{"doi-asserted-by":"crossref","unstructured":"Khokhani P, Rahmani NR, Kok A, Oner FC, Alblas J, Weinans H, et al. Use of Therapeutic Pathogen Recognition Receptor Ligands for Osteo-Immuno modulation. Materials (Basel) 2021; 14(5).;","key":"ref22","DOI":"10.3390\/ma14051119"},{"doi-asserted-by":"crossref","unstructured":"Huang J, Huang LQ, He HS, Yan J, Huang C, Wang R, et al. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes multiple myeloma resistance through the JAK2\/STAT3 pathway. Life Sci 2020; 257: 118088.;","key":"ref23","DOI":"10.1016\/j.lfs.2020.118088"},{"doi-asserted-by":"crossref","unstructured":"Solimando AG, Brandl A, Mattenheimer K, Graf C, Ritz M, Ruckdeschel A, et al. JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. Leukemia 2018; 32(3): 736-43.;","key":"ref24","DOI":"10.1038\/leu.2017.287"},{"doi-asserted-by":"crossref","unstructured":"Shang Y, Chen G, Liu L, Pan R, Li X, Shen H, et al. Clinical and immunological characteristics of high-risk double-hit multiple myeloma. BMC Cancer 2024; 24(1): 1373.;","key":"ref25","DOI":"10.1186\/s12885-024-13124-6"},{"doi-asserted-by":"crossref","unstructured":"Lu W, Xu S, Tan S, Lu L, Luo M, Xiao M. Comprehensive analysis and establishment of a prognostic model based on non-genetic predictors in multiple myeloma. Cancer Biomark 2023; 38(1): 49-59.;","key":"ref26","DOI":"10.3233\/CBM-220451"},{"unstructured":"Qi ZL, Luo YQ, Ding SM, Liu ZX. Efficacy of a Daltuzumab-containing Regimen in Patients with mSMART High-Risk Multiple Myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2024; 32(3): 774-9.;","key":"ref27"},{"doi-asserted-by":"crossref","unstructured":"Herrmann H, Sadovnik I, Eisenwort G, Rulicke T, Blatt K, Herndlhofer S, et al. Delineation of target expression profiles in CD34+\/CD38and CD34+\/CD38+ stem and progenitor cells in AML and CML. Blood Adv 2020; 4(20): 5118-32.;","key":"ref28","DOI":"10.1182\/bloodadvances.2020001742"},{"doi-asserted-by":"crossref","unstructured":"Zheng W, Liu D, Fan X, Powers L, Goswami M, Hu Y, et al. Potential therapeutic biomarkers in plasma cell myeloma: a flow cytometry study. Cytometry B Clin Cytom 2013; 84(4): 222-8.;","key":"ref29","DOI":"10.1002\/cyto.b.21083"},{"doi-asserted-by":"crossref","unstructured":"Sriram H, Kunjachan F, Khanka T, Gawai S, Ghogale S, Deshpande N, et al. Expression levels and patterns of B-cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent. Cytometry B Clin Cytom 2022; 102(6): 462-70.;","key":"ref30","DOI":"10.1002\/cyto.b.22099"},{"doi-asserted-by":"crossref","unstructured":"Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 2014; 123(20): 3128-38.;","key":"ref31","DOI":"10.1182\/blood-2013-10-535088"},{"doi-asserted-by":"crossref","unstructured":"Yan W, Liu Z, Liu J, Xia Y, Hu K, Yu J. Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies. Biomed Res Int 2020; 2020: 4241864.;","key":"ref32","DOI":"10.1155\/2020\/4241864"},{"unstructured":"Chu B, Wang Y, Lu M, Shi L, Gao S, Fang L, et al. Significance of CD319 and CD269 in Immunophenotyping and Minimal Residual Disease Detection in Patients with Multiple Myeloma. J Exp Hematol China 2021; 29(4): 1195-202.;","key":"ref33"},{"unstructured":"Li Q, Xu J, Jiang J. Changes in MDR1 and CD269 Expression in Bone Marrow Tissues of Patients with Multiple Myeloma and Their Clinical Significance. Shandong Med J 2019; 59(31): 77-9.;","key":"ref34"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Procena prognosti\u010dkog rizika smrtnog ishoda kod pacijenata sa multiplim mijelomom na osnovu CD184 i CD269 - retrospektivna analiza"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2025\/1452-82582506210C.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T11:16:28Z","timestamp":1757070988000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582506210C"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-56987","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"type":"print","value":"1452-8258"},{"type":"electronic","value":"1452-8266"}],"subject":[],"published":{"date-parts":[[2025]]}}}